| Methods |
Randomised trial with concurrent eligible patients outside of the RCT. The eligible but non‐RCT patients were not in the RCT because of patients refusal (24 patients) or patients not invited by their physician (24 patients). Patients with intermediate or high grade sarcoma. No losses to follow up. |
| Data |
Characteristics of non‐RCT patients compared to RCT patients who received the same treatment not presented. Twenty RCT patients received doxorubin treatment and 21 non‐RCT patients, 7 men and 14 women. |
| Comparisons |
Two RCT arms, both arms were compared with similarly treated eligible non‐RCT patients in a registry. The experimental RCT arm patients were treated with doxorubicin. The control RCT patients were under observation. |
| Outcomes |
Clinical outcomes were assessed in all patients. Patients were followed for up to 4 years. Main outcome reported in this study was disease free survival. |
| Notes |
No statistically significant difference was shown between the two RCT treatments. |
